Previous Study: TRIO020
Next Study: TRIO023

Studies & Results


A Randomized, multicenter, open-label, two-arm, Phase III neo-adjuvant study evaluating trastuzumab emtansine plus pertuzumab compared with chemotherapy plus trastuzumab emtansine and pertuzumab for patients with HER2-positive breast cancer

View FDA Study View EU Study


ASCO 2016

Hurvitz SA, et al.

Pathologic complete reponses rates after neoadjuvant Trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + Trastzumab + pertuzumab (TCH+P) treatment in patients with HER2-positive early breast cancer (KRISTINE/TRIO021)

SABCS 2016

de Haas SL, et al.

Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

SABCS 2017

Prat A, et al.

Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer.

ASCO 2019

Hurvitz SA, et al.

Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.

SABCS 2020

Hurvitz SA, et al.

Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at